Search All News
Seizures are usually considered a side effect of brain cancer, but a new Columbia University study of mice suggests they may also fuel the further growth of brain tumors.
Scientists at Columbia's Herbert Irving Comprehensive Cancer Center are using technologies developed to study cancer to look for drugs to treat COVID-19 and disarm the virus.
In a new study of mice, Columbia researchers found that an experimental drug that breaks down an amino acid slows pancreatic tumor growth by causing ferroptosis, an unusual form of cell death.
- July 3, 2019
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
- June 19, 2019
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
- April 17, 2019
Leading physician and researcher, Lisa Kachnic, MD, will lead Columbia's department of radiation oncology.
- April 3, 2019
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
- February 20, 2019
A clinical trial at Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
- December 19, 2018
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
- December 10, 2018
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.